Spain Biosimilars Market Size & Outlook, 2020-2027
Spain biosimilars market, 2016-2027 (US$M)
Related Markets
Spain biosimilars market highlights
- The Spain biosimilars market generated a revenue of USD 239.4 million in 2020 and is expected to reach USD 579.5 million by 2027.
- The Spain market is expected to grow at a CAGR of 13.5% from 2021 to 2027.
- In terms of segment, recombinant non-glycosylated proteins was the largest revenue generating product in 2020.
- Recombinant Glycosylated Proteins is the most lucrative product segment registering the fastest growth during the forecast period.
Biosimilars market data book summary
| Market revenue in 2020 | USD 239.4 million |
| Market revenue in 2027 | USD 579.5 million |
| Growth rate | 13.5% (CAGR from 2020 to 2027) |
| Largest segment | Recombinant non-glycosylated proteins |
| Fastest growing segment | Recombinant Glycosylated Proteins |
| Historical data | 2016 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins |
| Key market players worldwide | Amgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc |
Other key industry trends
- In terms of revenue, Spain accounted for 1.8% of the global biosimilars market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In Europe, Germany biosimilars market is projected to lead the regional market in terms of revenue in 2027.
- UK is the fastest growing regional market in Europe and is projected to reach USD 2,105.2 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biosimilars Market Scope
Biosimilars Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Spain biosimilars market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilars market will help companies and investors design strategic landscapes.
Recombinant non-glycosylated proteins was the largest segment with a revenue share of 53.51% in 2020. Horizon Databook has segmented the Spain biosimilars market based on recombinant non-glycosylated proteins, recombinant glycosylated proteins covering the revenue growth of each sub-segment from 2016 to 2027.
Strategic initiatives by market players are a major factor anticipated to fuel market growth over the forecast period. For instance, in October 2018, Mundipharma acquired Cinfa Biotech, which was engaged in development of biosimilars for different indications.
The acquisition provided Mundipharma with immediate access to the biosimilar Pelmeg. The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Pelmeg. This biosimilar of Neulasta has been developed for treatment of chemotherapy-induced neutropenia.
Reasons to subscribe to Spain biosimilars market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Spain biosimilars market databook
-
Our clientele includes a mix of biosimilars market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain biosimilars market , including forecasts for subscribers. This country databook contains high-level insights into Spain biosimilars market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
Spain biosimilars market size, by product, 2016-2027 (US$M)
Spain Biosimilars Market Outlook Share, 2020 & 2027 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
